Table 1

Characteristics of the patients with GCA and the healthy individuals at baseline

rGCA-CS (n=19)rGCA-TCZ (n=11)aGCA (n=11)p ValueControls* (n=10)p Value
Age, years: mean (SD)73 (10)69 (8)72 (10)0.4159 (10)<0.01
Sex, female: number (%)12 (63)9 (82)9 (82)0.484 (40)0.07
Race, white: number (%)17 (89)10 (91)11 (100)0.7811 (100)1.00
Relapsing disease: number (%)12 (63)11 (100)8 (73)0.06
Biopsy-proven disease: number (%)11 (58)5 (45)7 (64)0.78
Image compatible with large vessel vasculitis: number (%)†2 (11)4 (36)4 (36)0.16
Disease duration, months: median (IQR)25.5 (9.2; 54.1)35.7 (32.7; 70.4)34.9 (3.7; 60.3)0.73
Duration of CS treatment, months: median (IQR)18.4 (9.2; 54.1)28.4 (9.9; 67.9)34.5 (1.0; 58.0)0.90
Duration of TCZ treatment, months: median (IQR)18 (14.2; 28.5)
Prior MTX use: number (%)6 (32)4 (36)3 (27)1.00
CS dose at time of sampling, mg/day: mean (SD)15.7 (18.3)0.2 (0.4)8.0 (6.8)0.02‡
  • Analysis: Analysis of variance, Kruskal-Wallis, Student's t-test and Fisher's exact test.

  • *Controls versus all patients with GCA.

  • †Indicates MR angiography, CT angiography or positron emission tomography.

  • ‡rGCA-CS versus rGCA-TCZ.

  • aGCA, active GCA; CS, corticosteroids (prednisone); GCA, giant cell arteritis; MTX, methotrexate; rGCA-CS, GCA in remission on CS; rGCA-TCZ, GCA in remission on TCZ without or without CS; TCZ, tocilizumab.